Three-time champion Phil Mickelson will miss this year's Masters and step away from golf "for an extended period of time" because of a family health matter, the American says.
Three-time champion Phil Mickelson will miss this year's Masters and step away from golf "for an extended period of time" because of a family health matter, the American says.
In trading on Thursday, shares of Controladora Vuela Compania De Aviacion SAB de CV (Symbol: VLRS) crossed below their 200 day moving average of $7.10, changing hands as low as $6.94 per share. Controladora Vuela Compania De Aviacion SAB de CV shares are currently trading down
In trading on Thursday, shares of Controladora Vuela Compania De Aviacion SAB de CV (Symbol: VLRS) crossed below their 200 day moving average of $7.10, changing hands as low as $6.94 per share. Controladora Vuela Compania De Aviacion SAB de CV shares are currently trading down
Khanchit Khirisutchalual/iStock via Getty Images Is AI a net headwind or a tailwind? This seems to be the core question that is dogging the stock market this year, sparking the "SaaSpocalypse" that has wiped billions off the market cap of the software industry across companies both large and small. All in all, I continue to hold the belief that the SaaSpocalypse narrative is overblown, and investo...
Khanchit Khirisutchalual/iStock via Getty Images Is AI a net headwind or a tailwind? This seems to be the core question that is dogging the stock market this year, sparking the "SaaSpocalypse" that has wiped billions off the market cap of the software industry across companies both large and small. All in all, I continue to hold the belief that the SaaSpocalypse narrative is overblown, and investors should look to near-term quarterly results for hints whether certain software companies are disruptors or candidates for disruption. After all, customers of these software companies can vote with their feet, and if a certain platform is no longer compelling, customers can churn out, especially in this tough macroeconomy. UiPath ( PATH ), which was in the business of workflow and business process automation long before AI became a buzzword, looks like a company enjoying tailwinds. Though its share price has contracted ~30% since the start of the year (largely along with other software companies), the company's fundamentals have continued to shine, with healthy net expansion rates and ARR growth. Data by YCharts I last wrote a "Buy" article on UiPath in December, when the stock was trading at $18 per share. Needless to say, the sharp crash in the stock since then has disappointed me, and my buy call was ill-timed (as I certainly did not predict the SaaSpocalypse at the time). That said, such a sharp correction in any stock merits a fresh look, and especially when I assess the strength of UiPath's latest results against its freshly lowered valuation, I find an incredibly attractive bargain play. I'm reiterating my "Buy" rating here. Here's the reality that we need to confront with UiPath. Since agentic AI took off and automation became the core focus of CIOs and CFOs, UiPath's product is no longer incredibly unique. But at the same time, companies wishing to deploy automation tools now have two distinct options: DIY and build their own vibe-coded, agentic AI tools, or deplo...
In trading on Thursday, shares of Essential Properties Realty Trust Inc (Symbol: EPRT) crossed above their 200 day moving average of $30.98, changing hands as high as $31.07 per share. Essential Properties Realty Trust Inc shares are currently trading up about 1.2% on the day.
In trading on Thursday, shares of Essential Properties Realty Trust Inc (Symbol: EPRT) crossed above their 200 day moving average of $30.98, changing hands as high as $31.07 per share. Essential Properties Realty Trust Inc shares are currently trading up about 1.2% on the day.
Getty Images I've been a net seller of utility companies for the past year and more. I've sold off major positions and mostly left that in cash since then due to what I see as material overvaluation in most of the other spaces as well. While the company I cover today, Public Service Enterprise Group ( PEG ), has somewhat outperformed the market since, I don't consider it material enough to be a fa...
Getty Images I've been a net seller of utility companies for the past year and more. I've sold off major positions and mostly left that in cash since then due to what I see as material overvaluation in most of the other spaces as well. While the company I cover today, Public Service Enterprise Group ( PEG ), has somewhat outperformed the market since, I don't consider it material enough to be a failure. This is because my risk-free return over the same time has been comparable to keeping my money in the position. Seeking Alpha PEG RoR You can find that last article on the company here. As it stands, I believe the entire sector is overvalued for reasons that are unlikely to drive long-term returns. I have covered this in other utility articles, but I will cover it in this article again. That is not to say that PEG is a bad company. With a market capitalization of over $40B and a BBB+ in credit, it's a major player on the market. It's also very apt in terms of forecast accuracy - it doesn't miss much, and when it misses estimates, the few times, it actually ends up beating them. From that view, the company is very solid indeed. But as I am sure, if you follow my work, you know - this isn't enough to actually make it an attractive investment. In order for that we don't just need solid fundamentals, we also want what I would consider a good price for what we are buying. Years ago when I bought PEG, that was possible - that is why I had a return. As it stands, that is not possible unless you were to put the company at a premium that (in my view) it doesn't deserve, or unless you lower your hurdle rate for your expected return. Neither of those things is something that I am particularly interested in doing. In this article, I will update you on the following about 6-7 months, my thesis on the company to see at what price I'd be buying PEG. Public Service Enterprise Group - The growth is something I consider only conditionally realistic. This company certainly has what I w...
In trading on Thursday, shares of T1 Energy Inc (Symbol: TE) crossed below their 200 day moving average of $4.25, changing hands as low as $4.14 per share. T1 Energy Inc shares are currently trading off about 5.9% on the day. The chart below shows the one year performance of T
In trading on Thursday, shares of T1 Energy Inc (Symbol: TE) crossed below their 200 day moving average of $4.25, changing hands as low as $4.14 per share. T1 Energy Inc shares are currently trading off about 5.9% on the day. The chart below shows the one year performance of T
Debalina Ghosh/iStock via Getty Images Investors seeking refuge from stock volatility are turning to alternative ETFs like managed futures, crypto strategies, and commodity plays. Below is a list of the top 10 alternative ETFs ranked by their Seeking Alpha Quant Ratings. The list includes various alternative sub-classes, such as managed futures, relative value, global macro, and cryptocurrency str...
Debalina Ghosh/iStock via Getty Images Investors seeking refuge from stock volatility are turning to alternative ETFs like managed futures, crypto strategies, and commodity plays. Below is a list of the top 10 alternative ETFs ranked by their Seeking Alpha Quant Ratings. The list includes various alternative sub-classes, such as managed futures, relative value, global macro, and cryptocurrency strategies. The list is led by Breakwave Tanker Shipping ETF ( BWET ), which tops the rankings with a near-perfect Quant Rating of 4.99 and a “Strong Buy” designation. Defiance Oil Enhanced Options Income ETF ( USOY ) follows closely behind with a 4.78 rating, also earning a “Strong Buy” classification. The overall quality of the list remains strong throughout, with all selections maintaining “Buy” or “Strong Buy” ratings. From the top-ranked BWET down to the FT Vest Nasdaq-100 Buffer ETF ( QMAR ) at the bottom, every fund carries a Quant Rating above 4.20, indicating bullish sentiment across the board. Seeking Alpha’s Quant Ratings system grades ETFs based on their relative performance on key quantitative measures, including valuation, growth, momentum, and profitability. Ratings are given on a scale from 1 to 5, with any score of 3.5 or above considered a bullish rating and any score of 2.5 or below considered bearish. Here is the list: Breakwave Tanker Shipping ETF ( BWET ), Quant Rating: 4.99 Defiance Oil Enhanced Options Income ETF ( USOY ), Quant Rating: 4.78 YieldMax MSTR Short Option Income Strategy ETF ( WNTR ), Quant Rating: 4.40 First Trust Alternative Absolute Return Strat ETF ( FAAR ), Quant Rating: 4.38 Simplify Commodities Strategy No K-1 ETF ( HARD ), Quant Rating: 4.31 YieldMax AMD Option Income Strategy ETF ( AMDY ), Quant Rating: 4.28 Strategas Macro Thematic Opportunities ETF ( SAMT ), Quant Rating: 4.24 Invesco Managed Futures Strategy ETF ( IMF ), Quant Rating: 4.21 Simplify Currency Strategy ETF ( FOXY ), Quant Rating: 4.20 FT Vest Nasdaq-100 Buffer ETF ...
In trading on Thursday, shares of the GraniteShares YieldBOOST MSTR ETF (Symbol: MTYY) entered into oversold territory, changing hands as low as $4.62 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used
In trading on Thursday, shares of the GraniteShares YieldBOOST MSTR ETF (Symbol: MTYY) entered into oversold territory, changing hands as low as $4.62 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used
Andrii Yalanskyi/iStock via Getty Images Investment Overview The stock of ImmunityBio, Inc. ( IBRX ) has risen in value by ~80% since I last covered the company in January of this year , upgrading to a Buy rating - after two prior Hold calls. Immunity stock is currently priced at $7.3 per share, and the San Diego, California based biotechs' market cap valuation is presently ~$7.9bn. Stock is now u...
Andrii Yalanskyi/iStock via Getty Images Investment Overview The stock of ImmunityBio, Inc. ( IBRX ) has risen in value by ~80% since I last covered the company in January of this year , upgrading to a Buy rating - after two prior Hold calls. Immunity stock is currently priced at $7.3 per share, and the San Diego, California based biotechs' market cap valuation is presently ~$7.9bn. Stock is now up >250% year-to-date, >180% on a six-month basis, and >140% on a one-year basis, although on a one-month basis, it is down nearly 30%, having reached highs of nearly $12 per share in late February. Let's remind ourselves of the company's core business, as per its 2025 annual report / 10-K submission : ANKTIVA is our lead biologic product and a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein. We are commercializing ANKTIVA for the treatment of BCG-unresponsive NMIBC CIS (non muscle invasive bladder cancer, carcinoma in situ) with or without papillary tumors. ANKTIVA has received FDA Breakthrough Therapy designation for use in BCG-unresponsive NMIBC CIS in adult patients with or without papillary tumors. ANKTIVA is now approved in the U.S., UK, and Saudi Arabia for BCG-unresponsive NMIBC CIS with or without papillary tumors. In February 2026, the European Commission granted conditional marketing authorization in the EU for ANKTIVA for the same indication. Several positive pieces of news-flow have underpinned the stunning rise in the stock price over the past year. Immunity's Lung Cancer Data Triggers Bull Run At the end of 2025, shares traded ~$2, but on January 13th this year, the company shared some updates in relation to Anktiva as a potential therapy for non-small cell lung cancer ("NSCLC"), one of the largest indications in oncology. In combo with a checkpoint inhibitor, i.e., Merck's ( MRK ) PD-1 targeting Keytruda (pembrolizumab), or Bristol-Myers Squibb's ( BMY ) Opdivo (nivolumab), Anktiva demonstrated statistically significant immune rest...